selected publications
- Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancer. Cancer cell international. 2025 Academic Article GET IT
- Corrigendum to "International expert consensus on the clinical integration of circulating tumor cells in solid tumors" [Eur. J. Cancer 231 (2025) 116050]. 2025 GET IT
- Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis. NPJ breast cancer. 2025 Academic Article GET IT
- Cancer in a drop: Liquid biopsy highlights from the American Society of Clinical Oncology (ASCO) 2025 annual congress. The journal of liquid biopsy. 2025 Editorial Article GET IT
-
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study.
The oncologist.
2025
Academic Article
GET IT
Times cited: 1 -
Cancer in a drop: Advances in liquid biopsy in 2024.
Critical reviews in oncology/hematology.
2025
Review
GET IT
Times cited: 5 -
Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates.
JCO oncology practice.
2025
Review
GET IT
Times cited: 3 -
Mapping breast cancer therapy with circulating tumor cells: The expert perspective.
Breast (Edinburgh, Scotland).
2025
Review
GET IT
Times cited: 6 -
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.
JAMA network open.
2025
Academic Article
GET IT
Times cited: 10 -
Cancer in a drop: Liquid biopsy highlights from San Antonio Breast Cancer Symposium (SABCS) 2024.
The journal of liquid biopsy.
2025
Editorial Article
GET IT
Times cited: 1 -
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them.
Breast (Edinburgh, Scotland).
2024
Review
GET IT
Times cited: 8 -
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
European journal of cancer.
2024
Academic Article
GET IT
Times cited: 3 - Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?. Translational breast cancer research : a journal focusing on translational research in breast cancer. 2024 Editorial Article GET IT
-
Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors.
Critical reviews in oncology/hematology.
2024
Review
GET IT
Times cited: 10 -
Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine.
Current opinion in oncology.
2024
Review
GET IT
Times cited: 3 -
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials.
European journal of cancer.
2024
Academic Article
GET IT
Times cited: 2 -
The role of liquid biopsy as a catalyst for sustained progress in precision oncology - Perspective of the young committee of the international society of liquid biopsy.
The journal of liquid biopsy.
2024
Editorial Article
GET IT
Times cited: 8 -
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment.
Seminars in oncology.
2024
Review
GET IT
Times cited: 23 -
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.
Cancer treatment reviews.
2024
Review
GET IT
Times cited: 19 -
Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer.
Translational breast cancer research : a journal focusing on translational research in breast cancer.
2024
Review
GET IT
Times cited: 16 -
Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.
The oncologist.
2024
Academic Article
GET IT
Times cited: 6 - Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents. The oncologist. 2024 Review GET IT
- Cellular residual disease (CRD) in early breast cancer -Expanding the concept of minimal residual disease monitoring?. The journal of liquid biopsy. 2023 Review GET IT
- Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications. The journal of liquid biopsy. 2023 Review GET IT
-
Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancer.
International review of cell and molecular biology.
2023
Review
GET IT
Times cited: 7 -
HER2-positive breast cancer: cotargeting to overcome treatment resistance.
Current opinion in oncology.
2023
Academic Article
GET IT
Times cited: 2 -
Circulating Tumor DNA and Unique Actionable Genomic Alterations in the Longitudinal Monitoring of Metastatic Breast Cancer: A Case of FGFR2-KIAA1598 Gene Fusion.
2023
GET IT
Times cited: 1 -
Metaplastic breast cancer: an all-round multidisciplinary consensus.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP).
2023
Academic Article
GET IT
Times cited: 9 -
HER2-Low Breast Cancer: a New Subtype?.
Current treatment options in oncology.
2023
Review
GET IT
Times cited: 53 -
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases.
European journal of cancer.
2023
Academic Article
GET IT
Times cited: 9 -
Biology and Treatment of HER2-Low Breast Cancer.
Hematology/oncology clinics of North America.
2023
Review
GET IT
Times cited: 20 - Response to letter entitled: Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer". European journal of cancer. 2022 Letter GET IT
-
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?.
Cancer journal (Sudbury, Mass.).
2022
Review
GET IT
Times cited: 12 -
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?.
European journal of cancer.
2022
Review
GET IT
Times cited: 15 -
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.
Cancer treatment reviews.
2022
Review
GET IT
Times cited: 106 -
Different Response to Immunotherapy According to Melanoma Histologic Subtype.
Journal of immunotherapy (Hagerstown, Md. : 1997).
2022
Academic Article
GET IT
Times cited: 7 -
Evolution of low HER2 expression between early and advanced-stage breast cancer.
European journal of cancer.
2022
Academic Article
GET IT
Times cited: 154 -
Novel immune targets for the treatment of triple-negative breast cancer.
Expert opinion on therapeutic targets.
2021
Review
GET IT
Times cited: 19 -
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations.
Cancer treatment reviews.
2021
Review
GET IT
Times cited: 8 -
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021
Academic Article
GET IT
Times cited: 83 -
Antibody-drug conjugates in breast cancer: the chemotherapy of the future?.
Current opinion in oncology.
2020
Review
GET IT
Times cited: 38